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Abstract
Background: To initiate mucosal immune responses, antigens in the intestinal lumen must be transported into
gut-associated lymphoid tissue through M cells. Recently, it has been increasingly recognized that receptor activator
of NF-kB ligand (RANKL) controls M cell differentiation by interacting with RANK expressed on the sub-epithelium of
Peyer’s patches. In this study, we increased the number of M cells using soluble RANKL (sRANKL) as a potent
mucosal adjuvant.
Results: For efficient oral delivery of sRANKL, we constructed recombinant Lactococcus lactis (L. lactis) IL1403
secreting sRANKL (sRANKL-LAB). The biological activity of recombinant sRANKL was confirmed by observing
RANK-RANKL signaling in vitro. M cell development in response to oral administration of recombinant L. lactis was
determined by 1.51-fold higher immunohistochemical expression of M cell marker GP-2, compared to that of
non-treatment group. In addition, an adjuvant effect of sRANKL was examined by immunization of mice with
M-BmpB as a model antigen after treatment with sRANKL-LAB. Compared with the wild-type L. lactis group, the
sRANKL-LAB group showed significantly increased systemic and mucosal immune responses specific to M-BmpB.
Conclusions: Our results show that the M cell development by sRANKL-LAB can increase the antigen transcytotic
capability of follicle-associated epithelium, and thereby enhance the mucosal immune response, which implies that
oral administration of sRANKL is a promising adjuvant strategy for efficient oral vaccination.
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Background
The primary importance of oral vaccination is that many
infections start from the gastrointestinal tract, and in
these cases, topical application of a vaccine is usually re-
quired to induce a gut mucosal immune response [1].
However, oral vaccination often does not induce strong
IgA responses because the majority of antigens cannot
reach the mucosal inductive sites in the harsh digestive
conditions of the gastrointestinal tract. Further, ingested
antigens can induce a state of immune tolerance [2].
Given the poor immunogenicity of oral vaccines, the use
of an appropriate mucosal adjuvant may be important
for successful mucosal vaccination. Although some toxin
adjuvants including cholera toxin and E. coli heat-labile
toxin have been suggested as mucosal vaccine adjuvants,
safety concerns prevent their use in clinical applications.
Several cytokines including interleukin-6 [3], −12 [4], −15
[5] and Type I interferon-γ [6] have also been investigated
as safe and non-toxic mucosal adjuvants; however, they
have generally showed poor efficacy [3–6]. Hence, we
need a new approach to enhance mucosal immunity in re-
sponse to oral vaccines.
M cells are specialized epithelial cells in the follicle-
associated epithelium (FAE) that overlies gut-associated
lymphoid tissue (GALT) in Peyer’s patches. M cells
transport luminal organisms and particles passing
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through the intestine toward the GALT, and thus play a
central role in the initiation of an intestinal immune
response [7]. M cells account for only 10 % of FAE cells
in rodents, and 5 % in humans [8]. Due to the low
numbers of M cells in the intestinal tract, targeting M
cells using synthetic peptides [9] or pathogen-exploited
molecules [10, 11] could be a promising approach for
enhancing oral vaccine potency.
De novo differentiation of M cells is stimulated by
pathogens or foreign antigens, and induces up-
regulation of transport in Peyer’s patches, thereby
enhancing protective immune responses [12, 13]. In-
creasing the number of M cells can thus be a promising
biomimetic strategy to enhance the efficacy of an oral
vaccination. In recent, the importance of receptor activa-
tor of NF-kB ligand (RANKL) in controlling M cell dif-
ferentiation in Peyer’s patches has been increasingly
recognized [14–16]. RANKL is a member of the tumor
necrosis factor superfamily that has diverse functions
mediated by its interaction with RANK. In the body,
RANKL is produced as a transmembrane protein, but it
can be cleaved by several metalloproteinases [17, 18]
and released in its soluble extracellular form (sRANKL).
RANK-RANKL molecular signaling is an essential regu-
lator of bone remodeling, inducing the fusion of osteo-
clast progenitors into osteoclasts [19], and important in
the establishment of the thymic microenvironment and
the lymph node [20]. In Peyer’s patches, RANKL expres-
sion by subepithelial stromal cells shows a polarized pat-
tern, while RANK is expressed throughout the epithelial
cells of the small intestine [21]. This localization indi-
cates a possible function of RANKL in gut mucosal im-
munity. The role of RANKL in M cell development was
first demonstrated in vivo by the finding that RANKL
null mice have less than 2 % of wild-type levels of M
cells, and the number of M cells is rescued by adminis-
tration of exogenous RANKL for 7 days [15]. RANKL
induces the expression of the Ets transcription factor
Spi-B in epithelial precursors, which differentiate into M
cells [16].
Here, we examined the adjuvant potential of RANKL,
expecting that oral delivery of recombinant RANKL
would increase the number of M cells in the intestine.
For efficient oral delivery of sRANKL, Lactococcus lactis
(L. lactis) IL1403 was used as a live carrier because it
protects the recombinant protein from the low pH of
the stomach, and from enzymatic degradation during
passage through the intestinal tract. [22, 23]. The bio-
logical activity of sRANKLs was confirmed by observing
RANK-RANKL signaling in vitro. M cell development in
response to oral recombinant L. lactis was demonstrated
by staining with GP-2, an M cell marker. sRANKL en-
hanced the protective antibody response against a model
subunit antigen, M-BmpB (Brachyspira membrane
protein B conjugated with CKS9) [24] developed to
protect pigs from Brachyspira hydrosenteriae, which
causes muco-hemorrhagic dysentery [25].
Results
Production and secretion of sRANKLs from recombinant
L. lactis
The recombinant L. lactis IL 1403 expressing secretory
form of 181 amino acid sRANKL [15] (sRANKL-LAB)
was prepared using pILPtuf vector system previously
constructed by our group [26]. To permit the production
and secretion of protein, sRANKL was conjugated with
Usp45 signal peptide [3]. The schematic illustration of
gene constructs and expression vector system is shown
in Fig. 1a.
To examine the expression and secretion of sRANKLs
from recombinant sRANKL-LAB, the cytosolic and se-
creted protein fractions were separately prepared and
analyzed by Western blot. The bands of sRANKL pro-
tein from intracellular and extracellular (secreted) pro-
tein of L. lactis on Western blot are shown in Fig. 1b.
The sRANKLs was detected in lane C (commercial
sRANKL; ~28 kDa when glycosylated), lane 1 (cytosolic
sRANKL from sRANKL-LAB; ~23 kDa) while no
band was detected in lane 2 (wild-type L. lactis
IL1403). In addition, band of sRANKL was detected
from secreted protein fraction of sRANKL-LAB, con-
firming that conjugation of Usp45 signal peptide
greatly improved secretion of sRANKL. The secreted
protein had lower molecular weight than cytosolic
sRANKL because Usp45 signal peptide was detached
from protein while secreted from cells. For quantifica-
tion of sRANKL expression level, enzyme-linked-
immuno-sorbent assays (ELISA) was conducted. It
was determined that 109 CFU/ml (OD600nm = 2; cul-
ture volume = 500 ml) of sRANKL-LAB produces
193 ng/ml of sRANKL and secrets 60 ng/ml.
Physiological characterization of sRANKL-LAB
To examine the physiological characteristics of
sRANKL-LAB under metabolic burden of foreign pro-
tein expression, patterns of growth and lactic acid pro-
duction of sRANKL-LAB were analyzed during
cultivation at 30 °C. As shown in Fig. 2 all of groups
showed similar patterns of growth and pH decrease. Al-
though sRANKL-LAB showed slightly delayed growth
rate compared to wild-type L. lactis IL1403 (WT-LAB),
there was no statistical difference (Fig. 2a), and all of
groups reached stationary phase and minimum level of
pH at 10 h of cultivation (Fig. 2b). These results suggest
that production of sRANKL does not affect to normal
physiology in sRANKL-LAB.
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Validation of the biological activity of recombinant
sRANKLs in vitro
We tested the biological activity of recombinant
sRANKL produced by sRANKL-LAB by observing the
stimulation of RANK-RANKL signaling in vitro. RAW
264.7 cells (mouse leukemia monocyte macrophage)
were used for the assay because they express en-
dogenous RANK and are able to form osteoclast-like
cells in response to RANKL [27]. We analyzed the
expression of key molecules in the RANK-RANKL
signaling pathway (TRAF6, NFATc1 and TRAP) that
are related to osteoclast differentiation.
Culture media containing secreted sRANKL was dir-
ectly applied to RAW264.7 cells at 20 ng/ml of recom-
binant sRANKL. In addition, media from WT-LAB was
used as a negative control, and commercial sRANKL as
a positive control [28].
To optimize the concentration of sRANKL, a variety
of concentrations of commercial sRANKL was applied
to RAW264.7 cells, and the expression of RANK-
RANKL signaling molecules was analyzed. TRAF6,
NFATc1 and TRAP mRNA expression levels were in-
creased by increasing the concentration of purified
commercial sRANKL protein. We used 20 ng/ml in
our experiments because it sufficiently elicited RANK-
RANKL signaling (Additional file 1: Figure S1). As
shown in Fig. 3a-c, treatment with culture media con-
taining recombinant sRANKL (20 ng/ml) also induced
significant increases of TRAF6, NFATc1 and TRAP
mRNA compared with the WT-LAB group, implying
that recombinant sRANKL can elicit RANK-RANKL
signaling transduction. The efficacy of induction of
RANK-RANKL signaling molecules by recombinant
sRANKL was higher than commercial RANKL at the
Fig. 1 a Schematic diagram for construction of recombinant sRANKL expression vector system (modified from [3]). b Western blot for detecting
sRANKL from cell extracts (intracellular) and concentrated culture supernatants (extracellular). C: commercial sRANKL; lane 1: sRANKL-LAB; lane 2: WT-LAB
Fig. 2 Physiological characterization of recombinant sRANKL-LAB. a Growth of WT-LAB and sRANKL-LAB was traced by measuring OD value at a
wavelength of 600 nm. b The pH of WT-LAB and sRANKL-LAB was measured. The growth and pH were measured every 2 h for 12 h and at 24 h
after inoculation
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same concentration, which may be due to the differ-
ent origins of sRANKL and the different positions in
sRANKL expression sites.
M cell development induced by recombinant
sRANKL in vivo
sRANKL-LAB was orally administered to mice for con-
secutive seven days based on prior studies [15], and the
concentration of M cells in Peyer’s patches was analyzed
by whole mount immunohistochemistry (IHC). On day
8, Peyer’s patches were isolated from the small intestine,
and an M cell-specific marker GP-2 was used for immu-
nostaining. As shown in Fig. 4a, GP-2 activity was clearly
increased in the sRANKL-LAB group. The intensity of
GP-2 was 1.51-fold and 1.31-fold higher than the control
and WT-LAB group, when analyzed using the ImageJ
program. In addition, morphometric analysis [29] indi-
cated that the density of GP2+ cells was 1.68-fold and
1.54-fold higher than the control and WT-LAB group,
respectively (Fig. 4b). These results suggests that se-
creted sRANKL from orally administered sRANKL-LAB
efficiently induced M cell development in vivo. In
addition, the kinetics of M cells development by
sRANKL-LAB was observed by staining for GP-2 at
days 3, 5 and 7 after the first treatment with
sRANKL-LAB. An increase of GP-2 signal was ob-
served on day 3, and further increases of the signal
were shown on days 5 and 7 (Fig. 5).
Evaluation of recombinant sRANKL as a potent
mucosal adjuvant
To investigate the adjuvant effect of sRANKL, the model
antigen M-BmpB was administered orally after treat-
ment with sRANKL-LAB. The immunization schedule
and the time of sampling are shown in Fig. 6a. At days
21 and 28 after the first immunization, the levels of M-
BmpB-specific total serum IgG, IgG1, IgG2a, fecal IgA
and intestinal IgA were monitored by ELISA and
expressed as OD values. M-BmpB specific serum IgG in
the sRANKL-LAB group was 1.27-fold and 1.39-fold
higher than WT-LAB at days 21 and 28, respectively
(Fig. 6b and c). The level was 1.63-fold and 1.47-fold
higher than the PBS-treated groups at days 21 and 28, re-
spectively. Although significant differences in serum IgG
were not observed between the IgG levels of WT-LAB
and sRANKL-LAB groups, consistent enhancements of
IgG in the sRANKL-LAB group were observed. To in-
vestigate the effect of sRANKL on IgG subtypes, we
analyzed serum IgG1, a Th2 antibody isotype and
IgG2a, a Th1 isotype. Both IgG1 and IgG2a levels
were elevated by treatment with sRANKL-LAB; how-
ever, an alteration of Th1 and Th2 antibody balance
was not observed (Fig. 6d and e).
We also analyzed the effect of sRANKL-LAB treat-
ment on fecal and intestinal IgA production. Fecal IgA
levels in the sRANKL-LAB-treated group were signifi-
cantly higher than the WT-LAB-treated group (2.86-fold
and 2.53-fold greater at 21 and 28 days, respectively)
Fig. 3 qRT-PCR analysis of RANK-RANKL signaling-related gene
expression to validate the functional activity of sRANKL. The mRNA
expressions of a TRAF6, b NFATc1 and c TRAP were analyzed at day 6
after exposure of media of WT-LAB, commercial sRANKL (20 ng/ml) or
media of sRANKL-LAB containing 20 ng/ml of sRANKL to RAW 264.7
cells. The mRNA levels were normalized by GAPDH expression, and
expressed as relative gene expression compared to control. For
significance tests, a one-way analysis of variance (ANOVA) followed by
Tukey’s post-hoc test were used, and expressed as follows; *P < 0.05,
**P < 0.01, ***P < 0.001
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and the PBS-treated group (3.12-fold and 2.85-fold
greater at day 21 and 28, respectively) (Fig. 6f and g).
Similarly, at day 28 after the first immunization, oral ad-
ministration of sRANKL-LAB also enhanced intestinal
IgA levels (Fig. 6h). These results clearly show that M
cell development by pre-treatment with sRANKL-LAB
improved the induction of M-BmpB IgA and IgG
antibody responses.
Discussion
M cell induction by microbes and toxins is a protective
strategy that increases the gut’s ability to transport path-
ogens into lymph nodes, thus initiating a protective im-
mune response. In that context, we hypothesized that
stimulation of M cells before vaccination would affect
the mucosal immune response. RANKL−/− mice have
less than 2 % of wild-type levels of M cells in Peyer’s
patches, and the M cell deficit is corrected by adminis-
tration of exogenous RANKL, implying a critical role of
RANK-RANKL signaling in M cell development. The ef-
fect of oral administration of sRANKL on M cells, how-
ever, has not been investigated. In this work, sRANKL
was administered orally for two reasons: first, to meas-
ure its impact on the gastrointestinal tract where Peyer’s
patches exist, and second, to make administration easier.
We utilized L. lactis as a live oral delivery vehicle by
engineering it to express RANKL because L. lactis can
survive passage through the stomach and bile acid. In
general, the production of exogenous protein by LAB
can occur in three different locations: intracellular,
extracellular and cell wall-anchored [30]. It has been
generally accepted that cell-wall anchored antigens pro-
vide the highest immune responses due to easy process-
ing by antigen-presenting cells [30]. However, sRANKL
must directly interact with RANK expressed on the sub-
epithelium; thus, sRANKL-LAB was constructed to se-
cret sRANKL extracellularly by conjugating it with the
usp45 signal peptide, which targets proteins to the cyto-
plasmic membrane. Following cleavage of the usp45
peptide, the mature sRANKL protein is released extra-
cellularly, resulting in a direct interaction with the envir-
onment. We measured a 24 % secretion efficiency
(60 ng/ml) when analyzed by western blot and ELISA. In
addition, strong and constitutive expression of sRANKL
was driven by a Ptuf promoter, which was previously iso-
lated by our group [26] and determined to work in vitro
and in the gastrointestinal tract [3]. The high-level pro-
tein expression can overburden the metabolic capacities
of the host and may inhibit normal physiology. In spite
of high-efficiency sRANKL expression, the growth pat-
tern and lactic acid production of sRANKL-LAB were
similar to WT-LAB, suggesting that the basic physiology
of the recombinant strain was not severely modified.
Furthermore, we characterized the functional activity
of sRANKL produced from sRANKL-LAB in vitro.
RANKL is a key cytokine in osteoclast differentiation via
the RANK-RANKL signaling pathway. Therefore, the ex-
pression of RANK-RANKL signaling molecules is a good
indicator of the function of recombinant sRANKL. We
analyzed TRAF5, NFATc1 and TRAP gene expression as
Fig. 4 a Representative images for whole mount IHC of M cells in the FAE. At day 8 post-treatment of WT-LAB or sRANKL-LAB for consecutive
7 days, Peyer’s patches from mice of each group was isolated and stained with Alexa 488-labeled anti-GP-2, to observe M cell development. The
nucleus was stained with DAPI. Scale bar represents 100 μm. b and c the GP-2+ intensity and the GP-2+ cell density in the FAE of each group
were analyzed using ImageJ software. For significance tests, a one-way analysis of variance (ANOVA) followed by Tukey’s post-hoc test were used,
and expressed as follows; *P < 0.05, **P < 0.01, ***P < 0.001
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key molecules in the RANK-RANKL signaling pathway
by real-time quantitative reverse transcription PCR
(qRT-PCR). Binding of RANKL to RANK expressed on
RAW 264.7 results in recruitment of TRAF6 (tumor-ne-
crosis-factor-receptor-associated factor 6), which activates
NF-kB and JNK/c-Jun, and stimulates c-Fos induction.
NF-kB and c-Fos induce NFATc1 (nuclear factor of acti-
vated T cells, cytoplasmic 1) expression and in the nu-
cleus, NFATc1 works together with other transcription
factors to induce various osteoclast-specific genes includ-
ing TRAP (tartrate-resistant acid phosphatase) [31, 32].
The culture media containing recombinant sRANKL
and commercial sRANKL promoted the expressions of
RANK-RANKL signaling molecules, while the culture
media of WT-LAB did not induce the signaling pathway
when analyzed by qRT-PCR. Although the expression
levels of RANK-RANKL signaling-related genes were
higher in the recombinant sRANKL group than in the
commercial sRANKL group, a comparison of their func-
tional activity seems inappropriate because they have dif-
ferent positions and expression sites. The commercial
sRANKL contains amino acids 152–317, while our recom-
binant sRANKL contains amino acids 137–316 [15]. In
addition, the presence of erythromycin in the culture
medium of sRANKL-LAB may affect the expression of
RANK-RANKL signaling-related genes.
This study was inspired by a report demonstrating that
exogenous administration of RANKL nearly reconsti-
tutes the M cells of RANKL−/− mice, proving the M cell
developmental function of RANKL even after the im-
mune system has matured [15]. First, we examined
whether M cell development could be stimulated by oral
administration of sRANKL-LAB. Daily administration of
2 × 108 CFU (109 CFU/ml) of sRANKL-LAB for seven
days led to an approximately 1.5-fold increase of M cells
in Peyer’s patches. Given the Ptuf promoter activity in
Fig. 5 Representative images for whole mount IHC of M cells according to time. At day 3, 5 and 7 post-treatment of sRANKL-LAB, Peyer’s patches
were isolated from intestine and stained with Alex 488-labeled anti-GP-2, to observe the progress of M cell development by sRANKL. The nucleus
was stained with DAPI. Scale bar represents 100 μm
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Fig. 6 (See legend on next page.)
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the intestinal tract [3], it is reasonable to assume that
the secreted sRANKL elicited RANK-RANKL signal-
ing in the subepithelium. Second, the efficacy of
sRANKL-LAB as an oral adjuvant was validated by
oral vaccination of mice with M-BmpB, a model anti-
gen [24]. M-BmpB is comprised of an M cell target-
ing peptide isolated by phage display, and BmpB, an
outer envelope protein from Brachyspira. M-BmpB
was previously shown to target M cells and elicit
higher antibody responses than a conventional BmpB
antigen. Hence, it was hypothesized that an increase
of M cell numbers would enhance mucosal immune
responses. After induction of M cell development
with sRANKL-LAB, priming-boosting with M-BmpB
was conducted via the oral route. Treatment with the
M-BmpB antigen without sRANKL-LAB did not elicit
an antibody responses, which implies that oral vaccination
with soluble protein antigens requires an efficient mucosal
adjuvant. Although no significant difference was detected
in M-BmpB-specific serum IgG between the sRANKL-
LAB-treated group and the WT-LAB-treated group, a
trend of enhancement of serum IgG responses was ob-
served in the sRANKL-LAB group. The ratios of IgG2a to
IgG1, an indicator of Th1 or Th2 type responses, respect-
ively, were not altered by treatment with sRANKL-LAB.
Importantly, IgA in fecal extracts and intestinal lavage
fluid in the sRANKL-LAB group was significantly higher
than the other groups, which suggests that M cell devel-
opment by sRANKL increased the antigen transcytotic
capability of FAE, and thereby enhanced the mucosal im-
mune response. Our results demonstrate the potential of
our adjuvant candidate, sRANKL. Although oral adminis-
tration of sRANKL-LAB for seven days stimulated M cell
development and enhanced mucosal immune responses,
an optimal schedule of adjuvant treatment needs to be
further explored to maximize vaccine effect.
Conclusions
M cells play a central role in the initiation of an intes-
tinal immune response by transporting foreign antigen
to Peyer’s patches. In that sense, increasing the number
of M cells could be a promising strategy for enhancing
oral vaccine potency. Our approach was based on the
knowledge that RANKL signaling is sufficient to induce
the M cell development in the intestine. To utilize the
RANKL as novel oral adjuvant, we constructed recom-
binant L. lactis IL1403 expressing and secreting
sRANKL, and demonstrated its adjuvant potential in
vivo. We found that oral administration of sRANKL-
LAB enhances the systemic and mucosal immune re-
sponses to oral vaccine by increasing M cell number,
and thus facilitating the transcytotic ability of FAE.
Methods
Microorganism strains and growth conditions
E.coli DH5α and L. lactis IL1403 were used as host
strains. E.coli DH5α was grown in Luria-Bertani (LB)
medium (Difco, BD, USA) and recombinant E.coli with
ampicillin resistance were grown in LB medium with
100 μg/ml ampicillin at 37 °C with shaking at 250 rpm.
Wild type L. lactis IL 1403 was grown in M17 medium
(Difco, BD, USA) supplemented with 5 g/L of glucose
(M17G) without antibiotics, and recombinant L. lactis
was grown in M17G media with 5 μg/ml of erythro-
mycin at 30 °C with shaking.
Plasmid construction and transformation of L. lactis
To construct recombinant sRANKL-LAB, the pILPtuf
vector system previously constructed by our group was
used as a backbone [26]. The 181 amino acid sequence of
soluble RANKL was obtained from the literature [15] and
the codon usage was optimized for expression by L. lactis.
The gene encoding a Usp45 signal peptide was cloned up-
stream of the sRANKL gene to induce secretion of the
protein. The Nde1-Usp45-sRANKL-Xho1 gene fragment
cloned into the pGEM-B1 vector by Bioneer (South
Korea). To insert the Usp45-sRANKL gene fragment into
the pILPtuf vector, pGEM-B1 was digested by Ned1 and
Xho1 restriction enzymes, and introduced into the pIL252
backbone using the same restriction sites and T4 DNA
Ligase (NEB, USA). A schematic illustration of the expres-
sion constructs is shown in Fig. 1. After pellet paint copre-
cipitation to remove salts from the ligation products, the
vector was transformed into L. lactis IL 1403 by electro-
poration (2.5 kV, 10 μF, and 300Ω). The transformant
candidates were confirmed by DNA sequencing at the
National Instrumental Center for Environmental Manage-
ment (NICEM, South Korea).
(See figure on previous page.)
Fig. 6 Validation of sRANKL-LAB as oral adjuvant in vivo. a Schematic view of sRANKL-LAB treatment, priming-boosting and sampling schedule
(n = 5 in each group tested). b M-BmpB-specific total serum IgG levels at days of 21 and c 28, and d IgG1 subtype and e IgG2a subtype at day 28
after priming were determined by ELISA and expressed as OD value (450 nm). f M-BmpB-specific fecal IgA levels at days of 21 and g 28, and h
intestinal IgA levels at day 28 were measured with the same method. PBS/PBS; oral administration with PBS for every 7 days and immunization with
PBS. PBS/M-BmpP; oral administration with PBS for every 7 days and immunization with M-BmpB. WT/M-BmpP; oral administration with 2 × 108 CFU of
WT-LAB for every 7 days and immunization with M-BmpP. sRANKL/M-BmpP; oral administration with 2 × 108 CFU of sRANKL-LAB every 7 days and
immunization with M-BmpB. For significance tests, a one-way analysis of variance (ANOVA) followed by Tukey’s post-hoc test were used, and expressed
as follows; *P < 0.05, **P < 0.01, ***P < 0.001
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Confirmation of the expression and secretion of sRANKL
from LAB
The expression and secretion of sRANKL from sRANKL-
LAB was measured by SDS-PAGE and western blot. Com-
mercial sRANKL (amino acids 152–317 of RANKL)
obtained from Enzo Life Science (USA) was used as a con-
trol protein. Transformed L. lactis was cultured in M17G
media supplemented with erythromycin at 30 °C for over-
night, and the intracellular and secreted proteins were har-
vested separately. For preparation of intracellular protein,
cells were collected by centrifugation at 13,000 rpm for
1 min and broken in a bead beater. The secreted proteins
were precipitated from L. lactis culture supernatants by
16 % trichloroacetic acid (TCA), and the precipitants were
washed with ethanol and dissolved in Tris–HCl buffer.
The sample proteins separated by SDS-PAGE were
transferred onto a 0.2 μm nitrocellulose membrane
(Whatman, USA). The membrane was blocked with 5 %
(w/v) skim milk/TBST at RT for 1 h with shaking, and
subsequently incubated with a goat anti-mouse RANKL
antibody (R&D Systems, USA) at a dilution of 1:000 in
TBST at 4 °C overnight with shaking. The membrane was
further washed in TBST and incubated with anti-goat
antibody (Santa Cruz Biotechnology, USA) (1:1000 dilu-
tion) at room temperature (RT) for 1 h. The immunoreac-
tive proteins were visualized with ECL reagents
(Amersham, USA) using a ChemiDoc system (Bio-Rad,
USA). sRANKL expression was quantified using a mouse
RANKL solid sandwich ELISA kit (R&D Systems, USA)
according to the manufacturer’s instructions. In brief,
assay diluent was added to each well coated with RANKL
antibody, and a serial dilution of intracellular or extracel-
lular protein sample prepared by above-mentioned
method, or calibrator RANKL protein was added to each
well. After incubation for 2 h and washing step, enzyme-
conjugated antibodies were applied as detection anti-
bodies, and substrate solution was added each to convert
to colorimetric detectable form. After measuring OD
value of each well at 450 nm wavelength, dilutions of pro-
tein samples within detectable range were quantified.
Physiological characterization of sRANKL-LAB
sRANKL-LAB and WT-LAB were cultured in 50 ml of
M17G broth supplemented with erythromycin and
M17G broth without antibiotics, respectively. The op-
tical density (OD) of each sample was measured at a
wavelength of 600 nm every 2 h for 12 h and at 24 h
after inoculation to determine cell growth. The pH value
of the LAB cultures was measured simultaneously.
Validation of the biological activity of recombinant
sRANKL in vitro
RAW 264.7 cells obtained from the Korea Cell Line
Bank (KCLB) were seeded on cell culture dishes in
DMEM (Hyclone, USA) with 10 % fetal bovine serum
(FBS) (Hyclone, USA) and 1 % penicillin at a density of
2 × 104/ml. At four hours post seeding, the media was
changed to DMEM with 10 % FBS, 1 % P/S, and 30 ng/ml
of M-CSF with or without 20 ng/ml of sRANKL.
The recombinant sRANKL from the supernatant of
sRANKL-LAB cultures was prepared in a crude form as
described above and applied to RAW 264.7 cells at a
concentration of 20 ng/ml. The supernatant of WT-LAB
cultures and commercial sRANKL (20 ng/ml) were also
applied to RAW 264.7 cells for positive and negative
controls. At three days post treatment, the media was re-
placed by fresh media and the cells were incubated a fur-
ther three days. Total RNA was isolated from the
RAW264.7 cells using TRizol according to the manufac-
turer’s protocol and cDNA was synthesized using an
AccuPower® CycleScript RT PreMix (oligo dT) (Bioneer,
South Korea). qRT-PCR was conducted using TOPreal
qPCR 2X PreMIX (Enzynomics, South Korea) on iCycler
Real-Time Detection System (BioRad, USA) with spe-








AGGCCATGCCAGTGAGCTTC-3′. For quality assur-
ance, melting curve analysis was performed after complet-
ing the qRT-PCR. The amplicons from NFATc1, TRAF6,
TRAP and GAPDH each produced a single peak, demon-
strating reaction specificity and the absence of primer-
dimer artifacts.
Validation of the biological activity of recombinant
sRANKL in vivo
The effect of sRANKL-LAB on M cell development was
measured in vivo using six-week-old BALB/C mice follow-
ing the policy and regulations for the care and use of la-
boratory animal (Laboratory Animal Center, Seoul
National University, Korea). All protocols were reviewed
and approved by the Animal Care and Use Committee at
Seoul National University (SNU-130506-3). sRANKL-LAB
and WT-LAB for in vivo experiments were grown in
M17G broth at 30 °C overnight, and cell pellets were har-
vested by centrifugation when the OD600nm reached 2.0.
Cells were resuspended in 1 ml M17G broth at a concen-
tration of 109 CFU/ml and further incubated at 30 °C for
1 h. Thirty min before LAB administration, each mouse
was gavaged with 500 μl of a neutralizing agent (1.5 %
NaH2CO3) to prevent gastric acidity. LABs or PBS (200 μl)
were orally administered using an oral Zonde needle for
seven consecutive days (n = 5 mice/group and time point).
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One day after completing seven days of sRANKL-LAB
treatment, mice were killed and the Peyer’s patches of
the small intestine were collected for IHC. The detached
Peyer’s patches were incubated with PBST supplemented
with DNase (500 unit/ml) at 37 °C for 20 min, followed
by washing with cold PBST three times and fixation with
4 % (v/v) paraformaldehyde for 2 h at 4 °C. After wash-
ing three times, the tissue was blocked with 3 % goat
serum at RT for 1 h, and incubated with an
Alexa488-labeled GP-2 monoclonal antibody (1:400
dilution) at 4 °C overnight. The nucleus was stained
with 1 mg/ml of 4′, 6-Diamidine-2-phenylindole
(DAPI) and the tissue was mounted on cover-glass
bottom dishes. The fluorescence signals were observed
by a Confocal Laser Scanning Microscope (SP8X STED,
Leica, Germany). The relative GP-2 expression and GP-2+
cell density were evaluated using Image J software accord-
ing to the method described in [29]. A schematic illustra-
tion of the experimental steps of IHC is provided in
Additional file 1: Figure S2.
Immunization of mice in vivo
One day after treatment with sRANKL-LAB for seven
consecutive days (day 0), mice were orally immunized
with M-BmpB (n = 5 mice/group), prepared as described
in [3], using the immunization schedule as shown in
Fig. 2. The immunization groups were as follows: (i)
200 μl of PBS after treatment with PBS for seven days
(ii) 200 μg of M-BmpB after treatment with PBS for
seven days (iii) 200 μg of M-BmpB after treatment with
WT-LAB for seven days (iv) 200 μg of M-BmpB after
treatment with sRANKL-LAB for seven days. M-BmpB,
a model antigen [24], was prepared by culturing recom-
binant E.coli expressing a pET-M-BmpB plasmid, and
purifying M-BmpB using nickel affinity chromatography
(BioRad, USA). Thirty min before M-BmpB treatment,
each mouse was gavaged with a neutralizing agent as
described above, and subsequently given M-BmpB
dissolved in 200 μl of PBS using an oral Zonde
needle.
Blood and fecal samples were collected on days 21 and
28 after primary immunization. Blood samples were col-
lected from the intra-petrosal veins with a disposable
syringe and delivered into a sterilized tube. Serum was
separated by centrifugation at 12,000 rpm for 10 min,
and then used for detecting M-BmpB-specific immuno-
globulins. For fecal sample preparation, 5–8 fecal pellets
were collected and suspended in PBS. After intensive
vortexing, fecal samples were incubated at 4 °C over-
night, and the supernatants were collected by centrifuga-
tion at 14,000 rpm for 10 min. Intestinal lavage samples
were collected on day 28 after primary immunization.
Mice were orally administered 0.5 ml of the lavage solu-
tion (25 mM NaCl, 40 mM Na2SO4, 10 mM KCl,
20 mM NaHCO3, and 48.5 mM polyethylene glycol
(MW 3350)) four times at intervals of 15 min using a
blunt Zonde. At 30 min post-administration, 0.1 mg
pilocarpine was given to the mice intraperitoneally, and
the discharged intestinal contents (up to 0.5 ml) were
collected for measuring M-BmpB-specific IgA.
ELISA assay
The M-BmpB-specific immunoglobulins from serum or
fecal samples were measured by ELISA as previously de-
scribed [3]. In brief, purified M-BmpB was coated onto
96 well immuno-plates, and 100 μl of diluted serum or
fecal samples were loaded and incubated at RT for 2 h.
Diluted HRP-conjugated goat anti-mouse IgG, IgG1,
IgG2a or IgA (Santa Cruz Biotechnology, USA) was
added to each designated well at 37 °C for 1 h. TMB
substrate buffer (Santa Cruz Biotechnology, USA) was
added to each well, and stopped after 10 min by treating
with 100 μl of stop solution. The ELISA results are
expressed as the OD values measured at 450 nm by a
microplate reader (Infinite M200, TECAN, Germany)
using dilutions of 1:100 for serum, 1:2 for fecal extracts
and 1:3 for intestinal samples.
Statistical analysis
Statistical analysis was performed using OriginPro 9.0
software (OriginLab, USA). For significance tests, a one-
way analysis of variance (ANOVA) followed by Tukey’s
post-hoc test were used, and expressed as follows; *P <
0.05, **P < 0.01, ***P < 0.001.
Additional file
Additional fie 1: Figure S1. qRT-PCR analysis of RANK-RANKL signaling-
related gene expression to optimize the concentration of commercial
sRANKL. The mRNA expressions of TRAF6, NFATc1, and TRAP were analyzed
at day 6 after exposure of commercial sRANKL (20-50 ng/ml) to RAW 264.7
cells. The mRNA levels were normalized by GAPDH expression, and
expressed as relative gene expression compared to control. For significance
tests, a one-way analysis of variance (ANOVA) followed by Tukey’s post-hoc
test were used, and expressed as follows; *P < 0.05, **P < 0.01, ***P < 0.001.
Figure S2. Schematic illustration of IHC. Peyer’s patches were isolated
from small intestine and fixed with 4 % (v/v) paraformaldehyde for 2 h
at 4 °C. The tissues were blocked with 3 % goat serum at RT for 1 h and
incubated with Alexa488-labeled GP-2 monoclonal antibody (1:400
dilution) at 4 °C overnight. The tissues were mounted on coverglass
bottom dishes. (PDF 232 kb)
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